Clinical trialObsActive not recruiting
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation: a Retrospective Study
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 12 September 2026
- Expected end
- 12 December 2027
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- cfDNA Molecular Profiling
- Sponsor
- Other
- Results posted
- No
- Last update
- 16 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try